StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 5, 2026, 02:46 PM

ELI LILLY Q2 Revenue +48% to $23.0B; Net Income +25% to $7.1B

AI Summary

ELI LILLY reported strong second-quarter results with revenue increasing by 48% to $23.0 billion and net income rising by 25% to $7.1 billion. Diluted EPS grew by 26% to $7.94. The company continued its aggressive acquisition strategy, completing several business combinations and asset acquisitions, including Kelonia, Centessa, and Ventyx, and issuing $9.0 billion in long-term debt to support these activities.

Key Highlights

  • Q2 Revenue increased 48% to $22,974 million.
  • Q2 Net Income rose 25% to $7,095 million.
  • Q2 Diluted EPS grew 26% to $7.94.
  • Mounjaro revenue reached $9,943 million in Q2.
  • Zepbound revenue was $4,928 million in Q2.
  • Acquired Kelonia, Centessa, and Ventyx for over $12.6 billion.
  • Issued $9,000 million in long-term debt in May 2026.
  • Net cash from operating activities was $16,023 million for six months.